Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo

Nature Medicine

Volumn 9, Issue 5, 2003, Pages 540-547

  Blattman, Joseph N ^a   Grayson, Jason M ^a   Wherry, E John ^a   Kaech, Susan M ^a   Smith, Kendall A ^b   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; INFECTION CONTROL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS MENINGITIS;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES;

ANIMALIA; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; RNA VIRUSES;

EID: 0038025292     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm866     Document Type: Article

References (42)

1. Smith, K.A. Interleukin-2: inception, impact, and implications. Science 240, 1169-1176 (1988).
2. Gillis, S., Gillis, A.E. & Smith, K.A. The detection of a spleen focus-forming virus neoantigen by lymphocyte-mediated cytolysis. J. Exp. Med. 148, 18-31 (1978).
3. Van Parijs, L. et al. Uncoupling IL-2 signals that regulate T-cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11, 281-288 (1999).
4. Gillis, S. & Smith, K.A. Long term culture of tumour-specific cytotoxic T cells. Nature 268, 154-156 (1977).
5. Akbar, A.N. et al. Interleukin-2 receptor common γ-chain signaling cytokines regulate activated T-cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26, 294-299 (1996).
6. Lenardo, M.J. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353, 858-861 (1991).
7. Cousens, L.P., Orange, J.S. & Biron, C.A. Endogenous IL-2 contributes to T-cell expansion and IFN-γ production during lymphocytic choriomeningitis virus infection. J. Immunol. 155, 5690-5699 (1995).
8. Barouch, D.H. et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97, 4192-4197 (2000).
9. Kuroda, K. et al. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen. J. Immunol. 157, 1422-1431 (1996).
10. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
11. Suzuki, H. et al. Deregulated T-cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268, 1472-1476 (1995).
12. Willerford, D.M. et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
13. + memory T cells. J. Immunol. 165, 3031-3036 (2000).
14. + memory T cells by opposing cytokines. Science 288, 675-678 (2000).
15. Rosenberg, S.A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492 (1985).
16. Kovacs, J.A. et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350-1356 (1996).
17. Kovacs, J.A. et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur. J. Immunol. 31, 1351-1360 (2001).
18. Davey, R.T. et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 284, 183-189 (2000).
19. Jacobson, E.L., Pilaro, F. & Smith, K.A. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA 93, 10405-10410 (1996).
20. Murali-Krishna, K. et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177-187 (1998).
21. Matloubian, M., Kolhekar, S.R., Somasundaram, T. & Ahmed, R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 67, 7340-7349 (1993).
22. Zajac, A.J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
23. + T-cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2, 415-422 (2001).
24. Wong, P. & Pamer, E.G. Antigen independent CD8 T-cell proliferation. J. Immunol. 166, 5864-5868 (2001).
25. van Stipdonk, M.J., Lemmens, E.E. & Schoenberger, S.P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. 2, 381-382 (2001).
26. von Herrath, M.G., Yokoyama, M., Dockter, I., Oldstone, M.B. & Whitton, J.L. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70, 1072-1079 (1996).
27. Lau, L.L., Jamieson, B.D., Somasundaram, T. & Ahmed, R. Cytotoxic T-cell memory without antigen. Nature 369, 648-652 (1994).
28. + T cells during viral infection. J. Immunol. 166, 795-799 (2001).
29. Murali-Krishna, K. & Ahmed, R. Cutting edge: naive T cells masquerading as memory cells. J. Immunol. 165, 1733-1737 (2000).
30. Lotze, M.T. et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865-2875 (1985).
31. Lotze, M.T. et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58, 2764-2772 (1986).
32. Mier, J.W. et al. Induction of circulating tumor necrosis factor (TNF α) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J. Clin. Immunol. 8, 426-436 (1988).
33. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).
34. Wilson, J.D. et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 14, 225-233 (2000).
35. Jin, X. et al. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J. Infect. Dis. 181, 165-175 (2000).
36. + T-cell responses to CMV in HIV-1-infected subjects. Virology 279, 459-470 (2001).
37. + T cells in vivo by IL-15. Immunity 8, 591-599 (1998).
38. Smith, K. Interleukin 2 immunotherapy. in Therapeutic Immunology (eds. Austen, F., Burakoff, S., Rosen, F. & Strom, T.) 240-250 (Blackwell Science, Oxford, UK, 2001).
39. Smith, K.A. et al. In vivo assessment of antiviral reactivity in chronic HIV infection. HIV Clin. Trials 1, 16-22 (2000).
40. Smith, K.A. To cure chronic HIV infection, a new therapeutic strategy is needed. Curr. Opin. Immunol. 13, 617-624 (2001).
41. Yee, C., Ridell, S.R. & Greenberg, P.D. Prospects for adoptive T-cell therapy. Curr. Opin. Immunol. 9, 702-708 (1997).
42. Whitmire, J.K. et al. CD40-CD40 ligand costimulation is required for generating antiviral CD4 T-cell responses but is dispensable for CD8 T-cell responses. J. Immunol. 163, 3194-3201 (1999).